The 2016 “GLM 40 Edition” highlights Nevro in the area of Technology. Nevro is a medical device company headquartered in Redwood City, California. We have developed HF10™ therapy, an innovative, evidence-based neuromodulation platform for the treatment of chronic pain.
We started with a simple mission to help more patients suffering from chronic pain. At each stage of development, our research was subject to the highest levels of scientific rigor, resulting in a new therapy that has advanced the state of spinal cord stimulation (SCS).
We explored beyond traditional SCS frequencies (40–60 Hz) in search of better therapeutic outcomes. Combining high frequency at 10 kHz with a unique waveform and a specific treatment algorithm resulted in HF10 therapy: a paresthesia-free treatment proven to provide more pain relief to more patients in more pain areas.1
The Nevro® Senza® SCS System received CE mark in 2010, TGA approval in 2011, FDA approval in 2015, and is commercially available in Europe, Australia, and the United States. We are proud to recognize Nevro in the area of Technology for it’s level of excellence in the year of 2016!